Abstract
AbstractIn this paper, we explore dynamic market share and public healthcare costs of trastuzumab’s evergreening (subcutaneous) variant during introduction of trastuzumab’s competitive biosimilar variants in the Netherlands. We used a time series design to assess dynamic market share of trastuzumab’s evergreening variant after introducing trastuzumab’s biosimilar variants, focusing on the number of treatments and patients. The public healthcare costs of this evergreening strategy were estimated using administrative claims data. Our results show that the original trastuzumab was completely replaced by the subcutaneous and biosimilar variants. The uptake of the subcutaneous form peaked at 50% market share but after the introduction of biosimilars progressively reduced to a market share of 20%, resulting in a more competitive market structure. The public healthcare costs for trastuzumab significantly decreased after the introduction of the biosimilars. After the introduction of the biosimilars, a substantial price drop is visible, with the subcutaneous version, still under patent, also falling sharply in price but less strongly than the iv/biosimilar version. As the costs are publicly funded, we recommend a more explicit societal debate to consider if the potential benefits of subcutaneous Herceptin® (and other similar medicines) are worth the additional costs, and at which price it should be reimbursed as the part of the benefit package.
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference44 articles.
1. NZa (Dutch Healthcare Authority). Monitor Medisch specialistische zorg 2020 (in Dutch). NZa, Utrecht, the Netherlands (2020)
2. Dwivedi, G., Hallihosur, S., Rangan, L.: Evergreening: a deceptive device in patent rights. Technol. Soc. 32(4), 324–330 (2010)
3. Blackstone, E.A., Joseph, P.F.: The economics of biosimilars. Am. Health Drug Benefits 6(8), 469 (2013)
4. IQVIA. Protection Expiry and Journey into the Market. IQVIA, Durham, NC (2022)
5. Dutta, B., Huys, I., Vulto, A.G., Simoens, S.: Identifying key benefits in European Off-patent biologics and biosimilar markets: it is not only about price! BioDrugs: Clin. Immunother. Biopharm. Gene Ther. 34(2), 159–170 (2020)